CN116889597A - 一种缓解视疲劳改善视力的组合物及其制备方法 - Google Patents
一种缓解视疲劳改善视力的组合物及其制备方法 Download PDFInfo
- Publication number
- CN116889597A CN116889597A CN202311067038.6A CN202311067038A CN116889597A CN 116889597 A CN116889597 A CN 116889597A CN 202311067038 A CN202311067038 A CN 202311067038A CN 116889597 A CN116889597 A CN 116889597A
- Authority
- CN
- China
- Prior art keywords
- composition
- eye
- medlar
- pectase
- cellulase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- 208000003464 asthenopia Diseases 0.000 title claims abstract description 27
- 230000004438 eyesight Effects 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 21
- 108091005804 Peptidases Proteins 0.000 claims abstract description 15
- 239000004365 Protease Substances 0.000 claims abstract description 15
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims abstract description 15
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 14
- 235000017784 Mespilus germanica Nutrition 0.000 claims abstract description 14
- 235000000560 Mimusops elengi Nutrition 0.000 claims abstract description 14
- 235000003095 Vaccinium corymbosum Nutrition 0.000 claims abstract description 14
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims abstract description 14
- 235000007837 Vangueria infausta Nutrition 0.000 claims abstract description 14
- 235000021014 blueberries Nutrition 0.000 claims abstract description 14
- 239000012153 distilled water Substances 0.000 claims abstract description 14
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 13
- 240000000851 Vaccinium corymbosum Species 0.000 claims abstract description 13
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 13
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 13
- 239000011780 sodium chloride Substances 0.000 claims abstract description 13
- 108010059892 Cellulase Proteins 0.000 claims abstract description 12
- 229940106157 cellulase Drugs 0.000 claims abstract description 12
- 239000000284 extract Substances 0.000 claims abstract description 12
- 239000003889 eye drop Substances 0.000 claims abstract description 11
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229940116229 borneol Drugs 0.000 claims abstract description 9
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 9
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 9
- 210000000582 semen Anatomy 0.000 claims abstract description 9
- 230000004377 improving vision Effects 0.000 claims abstract description 6
- 102000004190 Enzymes Human genes 0.000 claims description 19
- 108090000790 Enzymes Proteins 0.000 claims description 19
- 229940088598 enzyme Drugs 0.000 claims description 19
- 244000182216 Mimusops elengi Species 0.000 claims description 13
- 235000013399 edible fruits Nutrition 0.000 claims description 12
- 239000000835 fiber Substances 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 12
- 238000005303 weighing Methods 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 7
- 230000000415 inactivating effect Effects 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 7
- 244000037364 Cinnamomum aromaticum Species 0.000 claims description 6
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- 238000004806 packaging method and process Methods 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 4
- 210000001508 eye Anatomy 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 12
- 206010051625 Conjunctival hyperaemia Diseases 0.000 abstract description 6
- 208000001491 myopia Diseases 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 230000004379 myopia Effects 0.000 abstract description 4
- 238000004140 cleaning Methods 0.000 abstract description 3
- 208000030533 eye disease Diseases 0.000 abstract description 3
- 241000894006 Bacteria Species 0.000 abstract description 2
- 238000009395 breeding Methods 0.000 abstract description 2
- 230000001488 breeding effect Effects 0.000 abstract description 2
- 230000007774 longterm Effects 0.000 abstract description 2
- 244000005700 microbiome Species 0.000 abstract description 2
- 240000002624 Mespilus germanica Species 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 10
- 230000006872 improvement Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 239000000047 product Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 3
- 206010013774 Dry eye Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 206010047513 Vision blurred Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940012356 eye drops Drugs 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 206010052143 Ocular discomfort Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 240000000572 Blumea balsamifera Species 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000003164 Diplopia Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020675 Hypermetropia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010023644 Lacrimation increased Diseases 0.000 description 1
- 241000218195 Lauraceae Species 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 241000779819 Syncarpia glomulifera Species 0.000 description 1
- 244000077233 Vaccinium uliginosum Species 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 208000019804 backache Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 208000029444 double vision Diseases 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 210000001145 finger joint Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 201000006318 hyperopia Diseases 0.000 description 1
- 230000004305 hyperopia Effects 0.000 description 1
- 230000009474 immediate action Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 230000004317 lacrimation Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000008897 memory decline Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 239000001739 pinus spp. Substances 0.000 description 1
- 201000010041 presbyopia Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 229940036248 turpentine Drugs 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Ophthalmology & Optometry (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种缓解视疲劳改善视力的组合物,包括如下组分:冰片提取物:3~5g;蓝莓:50g;决明子:100g;枸杞:50g;透明质酸:0.2~3g;氯化钠:0.2~3g;纤维素酶:10~20g;果胶酶:10~20g;复合蛋白酶:10~20g;其余为蒸馏水。本发明眼用组合物效率较高、处方简单、生产成本低廉,具有清洁眼部及隐形眼镜的作用,针对青少年眼部及佩戴隐形眼镜造成的眼部不适,用眼疲劳、结膜充血具有一定的缓解作用,并能有效改善视力。长期使用本发明滴眼剂,具有预防细菌及微生物滋生所造成的疲劳、近视及预防眼部疾病的作用。
Description
技术领域
本发明涉及护眼产品领域,尤其涉及一种缓解视疲劳改善视力的组合物及其制备方法。
背景技术
视疲劳表现为用眼后的视觉障碍,并伴有眼部不适及大量全身症状,导致患者无法正常视作业,视疲劳最主要的症状是眼干涩、异物感、眼皮沉重、视物模糊、畏光流泪、胀痛、眼部充血,视疲劳未及时干预严重时可出现全身症状,如头晕、头痛、恶心、精神萎靡、注意力不集中、记忆力下降、食欲减退、手指关节麻木、颈肩腰背酸痛、近视度数加深、青光眼加重、少数患者出现复视或立体视觉功能障碍和眼压升高。
目前隐形眼镜市场趋于成熟,近视人群选择佩戴隐形眼镜的比例也随着消费水平的提高不断增加,如长时间佩戴隐形眼镜可能会出现眼睛抵抗力下降、视疲劳,甚至引发干眼症。另外隐形眼镜长期贴附在眼球上,还会使神经末梢麻痹,导致角膜知觉减退。
目前市场上多种产品有些是基于清洁眼部的机理来保护眼睛,但是还是存在着多方面的不足。尤其是中药配方的产品,多数存在有效率较差、处方过于复杂、生产成本昂贵的问题。
发明内容
本发明的目的是提供一种缓解视疲劳改善视力的组合物及其制备方法,该眼用组合物效率较高、处方简单、生产成本低廉,具有清洁眼部及隐形眼镜的作用,针对青少年眼部及佩戴隐形眼镜造成的眼部不适,用眼疲劳、结膜充血具有一定的缓解作用,并能有效改善视力。长期使用本发明滴眼剂,具有预防细菌及微生物滋生所造成的疲劳、近视及预防眼部疾病的作用。
本发明提供了一种缓解视疲劳改善视力的组合物,包括如下组分:冰片提取物:3~5g;蓝莓:50g;决明子:100g;枸杞:50g;透明质酸:0.2~3g;氯化钠:0.2~3g;纤维素酶:10~20g;果胶酶:10~20g;复合蛋白酶:10~20g;其余为蒸馏水。
进一步地,所述组合物的优选组分为:冰片提取物:3g;蓝莓:50g;决明子:100g;枸杞:50g;透明质酸:1g;氯化钠:1g;纤维素酶:15g;果胶酶:15g;复合蛋白酶:15g;复合蛋白酶:15g;其余为蒸馏水。
本发明还提供了一种所述缓解视疲劳改善视力的组合物的制备方法,包括如下步骤:
(1)取蓝莓50g、决明子100g、枸杞50g干燥粉碎,过20~200目筛,得到纤维果粉;
(2)称取纤维素酶、果胶酶和复合蛋白酶,混合均匀,得到混合酶;
(3)称取步骤(1)得到的纤维果粉,按料液比1:(8~10)的质量体积比加入蒸馏水,混合均匀后加入步骤(2)得到的混合酶;37℃水浴1~6h后,75~95℃灭酶5~15min,得到酶解后的溶液;过滤收集滤液后备用;
(4)加入冰片提取物,氯化钠,透明质酸搅拌均匀后调节pH6~7后灭菌,分装即得滴眼剂。
借由上述方案,通过缓解视疲劳改善视力的组合物及其制备方法,具有如下技术效果:
1)该改善视力组合物能清洁眼球,减轻眼睛疲劳;同时该组合物可避免视网膜在吸收光线的时候受到氧化伤害,降低患白内障的几率,补充本品对视网膜色素变性有助益。
2)该组合物可同时应用于长时间使用电脑的人士、经常夜间驾驶的人士、长时间看电视及使用游戏机的人士、担心视力衰退的人士等,对于近视、远视、老花眼、视网膜退化均有效果。
3)该眼用组合物制剂,处方简单,组方合理,操作工艺简单,生产成本低,没有任何污染,原料安全无毒副作用,具有清洁眼部及隐形眼镜的作用,有效率高,对眼疲劳及视力均有改善作用。
上述说明仅是本发明技术方案的概述,为了能够更清楚了解本发明的技术手段,并可依照说明书的内容予以实施,以下以本发明的较佳实施例并配合附图详细说明如后。
附图说明
图1是本发明缓解视疲劳改善视力的组合物制备方法的流程图。
具体实施方式
下面结合附图和实施例,对本发明的具体实施方式作进一步详细描述。以下实施例用于说明本发明,但不用来限制本发明的范围。
本实施例提供了一种缓解视疲劳改善视力的组合物,包括如下重量份原料制备而成:冰片提取物:3~5g;蓝莓:50g;决明子:100g;枸杞:50g;透明质酸:0.2~3g;氯化钠:0.2~3g;纤维素酶:10~20g;果胶酶:10~20g;复合蛋白酶:10~20g;其余为蒸馏水。
优选地,所述组合物的重量份原料的比例为:冰片提取物:3g;蓝莓:50g;决明子:100g;枸杞:50g;透明质酸:1g;氯化钠:1g;纤维素酶:15g;果胶酶:15g;复合蛋白酶:15g;复合蛋白酶:15g;其余为蒸馏水。
参图1所示,缓解视疲劳改善视力的组合物的制备方法如下:
(1)取蓝莓50g、决明子100g、枸杞50g干燥粉碎,过20~200目筛,得到纤维果粉;
(2)称取纤维素酶、果胶酶和复合蛋白酶,混合均匀,得到混合酶;
(3)称取步骤(1)得到的纤维果粉,按料液比1:(8~10)的质量体积比加入蒸馏水,混合均匀后加入步骤(2)得到的混合酶;37℃水浴1~6h后,75~95℃灭酶5~15min,得到酶解后的溶液;过滤收集滤液后备用;
(4)加入冰片提取物,氯化钠,透明质酸搅拌均匀后调节pH6~7后灭菌,分装即得滴眼剂。
实施例1:
(1)称取蓝莓50g、决明子100g、枸杞50g干燥粉碎,过80目筛,得到纤维果粉;
(2)称取纤维素酶、果胶酶和复合蛋白酶,混合均匀,得到混合酶;
(3)称取步骤(1)得到的纤维果粉,按料液比1:8的质量体积比加入蒸馏水,混合均匀后加入步骤(2)得到的混合酶;37℃水浴4h,80℃灭酶10min,得到酶解后的溶液;过滤收集滤液后备用。
(4)加入冰片提取物,氯化钠,透明质酸搅拌均匀后调节pH6~7后灭菌,分装即得滴眼液。
实施例2:
(1)称取蓝莓50g、决明子100g、枸杞50g干燥粉碎,过150目筛,得到纤维果粉;
(2)称取纤维素酶、果胶酶和复合蛋白酶,混合均匀,得到混合酶;
(3)称取步骤(1)得到的纤维果粉,按料液比1:10的质量体积比加入蒸馏水,混合均匀后加入步骤(2)得到的混合酶;37℃水浴2h,90℃灭酶5min,得到酶解后的溶液;过滤收集滤液后备用。
(4)加入冰片提取物,氯化钠,透明质酸搅拌均匀后调节pH6~7后灭菌,分装即得滴眼液。
下面对主要原料的功能进行说明:
枸杞:滋补肾阴、清肝明目。用于肝肾阴虚证。本品甘平质润,平补肝肾,有滋补强壮作用。
蓝莓:具有防止脑神经老化、保护视力、强心、抗癌、软化血管、增强人机体免疫等功能,营养成分高。
决明子:决明子味苦、甘、咸,性微寒,入肝、肾、大肠经;润肠通便。降脂明目,治疗便秘及高血脂,高血压。
冰片:是由菊科艾纳香茎叶或樟科植物龙脑樟枝叶经水汽蒸馏并重结晶而得,亦有用松节油经一系列化学方法工艺而得。其可用于闭证神昏、用于目赤肿瘤,喉痹口疮、用于疮疡肿痛,溃后不敛等。
对比例1:
本对比例提供一种护眼组合物,其组分与实施例1的区别仅在于不含枸杞,其缺少的质量按比例分配至蓝莓及决明子的质量上,其他条件保持不变。制备方法参照实施例1。
对比例2:
本对比例提供一种护眼组合物,其组分与实施例1的区别仅在于不含冰片,其缺少的质量按比例分配至氯化钠及透明质酸的质量上,其他条件保持不变。制备方法参照实施例1。
对比例3:
本对比例提供了一种护眼组合物的制备方法,其制备方法与实施例1的区别在于步骤(3),称取步骤(1)得到的纤维果粉,按料液比1:8的质量体积比加入蒸馏水,混合均匀后加入步骤(2)得到的混合酶;50℃水浴30min,80℃灭酶10min,得到酶解后的溶液;过滤收集滤液后备用。其他步骤及条件保持不变,添加组分参照实施例1。
对比例4:
本对比例提供了一种护眼组合物的制备方法,其制备方法与实施例1的区别在于步骤(3),称取步骤(1)得到的纤维果粉,按料液比1:12的质量体积比加入蒸馏水,混合均匀后加入步骤(2)得到的混合酶;37℃水浴4h,80℃灭酶10min,得到酶解后的溶液;过滤收集滤液后备用。其他步骤及条件保持不变,添加组分参照实施例1。
试验例:
本发明所述的滴眼液按滴眼剂的常规使用方法使用。选择视物模糊,长期用眼、视力易疲劳的自愿受试者,年龄在10~40岁之间,排除患有眼部疾病者,一周内未使用与受试功能相关的产品,对以上实施例1~2及对比例1~4进行人群使用试验。试验共分7组,每组10人,各组之间年龄层及眼部不适等情况水平保持均衡,使各组之间具有可比性。1~6组分别使用实施例1~2和对比例1~4,7组使用对照组(闪亮复方门冬维甘滴眼液),一日2~3次,每次1滴,持续4周。在使用期间,受试者若出现不适症状应立即采取措施并停止试验。在整个使用期间禁止使用其他同功能类型药物或产品。
试用结束后评价各组人员视疲劳(眼干涩、眼胀痛)、结膜充血,视物模糊改善情况。试用评分表如表1所示:
表1受试者情况改善评分表
本发明针对视疲劳的发病机制及临床症状,以局部外用药的方式,起到缓解视疲劳、结膜充血,改善视力的作用。
下面结合实验例结果对本发明作进一步的阐述。
临床应用统计如下表2,各组分不同症状改善率为:轻微改善以上人数/总人数:
表2各试验组受试人群症状改善率统计
本发明提供的用于改善视力的滴眼液及其制备方法与用途,经过了多例的临床试验,对其每味药物的功能与主治以及根据现代中西医药理学的研究而形成的一种组方,具有配方合理、制作方法简单易行、易于推广的特点,起到缓解视疲劳、结膜充血、改善视力的效果,并且无不良反应和副作用。
以上所述仅是本发明的优选实施方式,并不用于限制本发明,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明技术原理的前提下,还可以做出若干改进和变型,这些改进和变型也应视为本发明的保护范围。
Claims (3)
1.一种缓解视疲劳改善视力的组合物,其特征在于,包括如下组分:冰片提取物:3~5g;蓝莓:50g;决明子:100g;枸杞:50g;透明质酸:0.2~3g;氯化钠:0.2~3g;纤维素酶:10~20g;果胶酶:10~20g;复合蛋白酶:10~20g;其余为蒸馏水。
2.根据权利要求1所述的缓解视疲劳改善视力的组合物,其特征在于,所述组合物的优选组分为:冰片提取物:3g;蓝莓:50g;决明子:100g;枸杞:50g;透明质酸:1g;氯化钠:1g;纤维素酶:15g;果胶酶:15g;复合蛋白酶:15g;复合蛋白酶:15g;其余为蒸馏水。
3.一种权利要求1或2所述缓解视疲劳改善视力的组合物的制备方法,其特征在于,包括如下步骤:
(1)取蓝莓50g、决明子100g、枸杞50g干燥粉碎,过20~200目筛,得到纤维果粉;
(2)称取纤维素酶、果胶酶和复合蛋白酶,混合均匀,得到混合酶;
(3)称取步骤(1)得到的纤维果粉,按料液比1:(8~10)的质量体积比加入蒸馏水,混合均匀后加入步骤(2)得到的混合酶;37℃水浴1~6h后,75~95℃灭酶5~15min,得到酶解后的溶液;过滤收集滤液后备用;
(4)加入冰片提取物,氯化钠,透明质酸搅拌均匀后调节pH6~7后灭菌,分装即得滴眼剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311067038.6A CN116889597A (zh) | 2023-08-23 | 2023-08-23 | 一种缓解视疲劳改善视力的组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311067038.6A CN116889597A (zh) | 2023-08-23 | 2023-08-23 | 一种缓解视疲劳改善视力的组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116889597A true CN116889597A (zh) | 2023-10-17 |
Family
ID=88312282
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311067038.6A Pending CN116889597A (zh) | 2023-08-23 | 2023-08-23 | 一种缓解视疲劳改善视力的组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116889597A (zh) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1628759A (zh) * | 2004-10-13 | 2005-06-22 | 凌沛学 | 一种治疗视疲劳综合症的中药制剂及其制备方法 |
CN102626224A (zh) * | 2012-04-24 | 2012-08-08 | 哈尔滨工业大学 | 野生浆果与中药复合的明目药剂及其制备方法 |
CN103372099A (zh) * | 2012-04-12 | 2013-10-30 | 启东钛力眼镜制品有限公司 | 明目滴眼液 |
CN105106427A (zh) * | 2015-08-18 | 2015-12-02 | 陈小平 | 缓解眼疲劳的眼药水及制备方法 |
CN107028973A (zh) * | 2017-05-12 | 2017-08-11 | 浙江工贸职业技术学院 | 一种缓解视疲劳用滴眼液及其制备方法 |
CN107412570A (zh) * | 2017-08-18 | 2017-12-01 | 湖北李时珍现代生物医药集团有限公司 | 一种含有艾草的中药护眼药液及其制备方法和眼贴 |
CN108524667A (zh) * | 2018-05-23 | 2018-09-14 | 南京中生生物科技有限公司 | 一种具有缓解视疲劳作用的叶黄素酯组合物及其制备方法 |
CN109010761A (zh) * | 2018-08-15 | 2018-12-18 | 王小平 | 一种缓解视疲劳和提高视力的眼部外用药及其制备方法 |
-
2023
- 2023-08-23 CN CN202311067038.6A patent/CN116889597A/zh active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1628759A (zh) * | 2004-10-13 | 2005-06-22 | 凌沛学 | 一种治疗视疲劳综合症的中药制剂及其制备方法 |
CN103372099A (zh) * | 2012-04-12 | 2013-10-30 | 启东钛力眼镜制品有限公司 | 明目滴眼液 |
CN102626224A (zh) * | 2012-04-24 | 2012-08-08 | 哈尔滨工业大学 | 野生浆果与中药复合的明目药剂及其制备方法 |
CN105106427A (zh) * | 2015-08-18 | 2015-12-02 | 陈小平 | 缓解眼疲劳的眼药水及制备方法 |
CN107028973A (zh) * | 2017-05-12 | 2017-08-11 | 浙江工贸职业技术学院 | 一种缓解视疲劳用滴眼液及其制备方法 |
CN107412570A (zh) * | 2017-08-18 | 2017-12-01 | 湖北李时珍现代生物医药集团有限公司 | 一种含有艾草的中药护眼药液及其制备方法和眼贴 |
CN108524667A (zh) * | 2018-05-23 | 2018-09-14 | 南京中生生物科技有限公司 | 一种具有缓解视疲劳作用的叶黄素酯组合物及其制备方法 |
CN109010761A (zh) * | 2018-08-15 | 2018-12-18 | 王小平 | 一种缓解视疲劳和提高视力的眼部外用药及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109091675B (zh) | 一种复方低浓度阿托品类药物滴眼液及其制备方法 | |
CN103417733B (zh) | 一种缓解视疲劳的药物组合物 | |
CN101322743A (zh) | 一种能修复眼部病变损伤改善视力疲劳的制剂及其制备方法 | |
CN102225087A (zh) | 一种强效护眼的叶黄素复方制剂 | |
CN102139038A (zh) | 一种治疗眼病的中药制剂 | |
CN102763847A (zh) | 一种具有缓解视疲劳的保健食品及其制备方法 | |
CN103300373A (zh) | 叶黄素原花青素复合软胶囊及其制备方法 | |
CN104225265A (zh) | 一种缓解视力疲劳的中药组合物 | |
CN110496215A (zh) | 一种治疗老视的水性滴眼液及其制备方法 | |
CN109010790A (zh) | 一种用于改善眼部疲劳的组合物及其应用 | |
CN105983004A (zh) | 一种缓解视疲劳的组合物和制备方法 | |
CN116889597A (zh) | 一种缓解视疲劳改善视力的组合物及其制备方法 | |
CN106490619A (zh) | 一种缓解视疲劳、预防视力减退的保健食品 | |
US20210228516A1 (en) | Eye drops that cure cataracts presbyopia and | |
CN113413415B (zh) | 一种羊毛甾醇滴眼液及其制备方法 | |
CN113925828A (zh) | 一种龙脑洗眼液 | |
CN211095171U (zh) | 一种近视老花眼提升视力的效果眼罩 | |
CN104436156A (zh) | 一种视力保护剂叶黄素眼用制剂其制备工艺 | |
CN105983006A (zh) | 一种缓解视疲劳的组合物及制备方法 | |
CN102343012B (zh) | 一种用于眼科疾病治疗的组合物及制备方法 | |
CN101856429B (zh) | 一种具有缓解视疲劳功能的药物组合物及其制备方法 | |
CN112273495A (zh) | 一种清晰看远快速恢复好视力的茶叶组合物 | |
CN111346034A (zh) | 一种中草药眼部按摩膏 | |
CN108273037A (zh) | 一种含衣鱼蛋白的抗疲劳滴眼液 | |
CN111956737A (zh) | 一种养目中药、制备方法及中式养目设备 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |